BioWorld
  • BioWorld Home
  • About Us
  • Contact BioWorld

BioWorld

Just another weblog
  • Blog Home
  • Editorial Staff
  • Editor’s Picks
  • Contact Us
  • Log In

In Kidney, the Name Game not Just ‘A-Cute’ Switcheroo

October 31, 2012 – 1:42 pm | By Randy Osborne | No comments yet

H

I was on the phone last week with Rick Andrews, president and CEO of Thrasos, about acute kidney injury (AKI), and how it’s no longer called “acute renal failure,” the latter phrase having been scrapped in recent years.

Share

Read more
Posted in acute kidney injury, Clinic, Clinical Trial | Tagged AKI, MSH, QPI, THR

The Times They Are A-Changin’

October 15, 2012 – 1:15 pm | By Peter Winter | No comments yet

T

Kudos to the folks at Biotechnology Industry Organization (BIO) for selecting the industry’s “hot button” issues for panel discussions at the annual BIO Investor Forum (BIF) just concluded in San Francisco. In years past it has been my experience that…

Share

Read more
Posted in Biotech conferences, Biotechnology, Biotechnology Industry Organization | Tagged BIF, Bob Dylan, San Francisco, Srini Akkaraju

Force Care Foundation Brings Military Opportunities to Bio-Entrepreneurs

October 10, 2012 – 3:54 pm | By Guest Contributor | 1 comment

Blog 10-10-12

Last autumn, I was searching for a way to get rid of the nerve-zapping pain that hit every time the barometer made a steep jump. My face full of post-plane crash titanium and regenerated bone acted like a weather station….

Share

Read more
Posted in Financing, traumatic brain injury | Tagged Army Acquisitions, Force Care, MRMC, Paul Michaels

What Global Financial Crisis? Capital Markets Back Biotechs

October 3, 2012 – 11:19 am | By Peter Winter | No comments yet

P

It is that time of year again when we take the pulse of the industry at the close of the third quarter. Overall we find that it is performing well, more so for public biotechs than private ones. Despite the…

Share

Read more
Posted in Biotechnology, Financing, venture captial | Tagged IPO

A Modest Proposal to the IgNobel Committee

September 26, 2012 – 3:27 pm | By Anette Breindl | No comments yet

A

I always love reading about the IgNobel Prizes. The stated goal of the prize is to reward research that “first makes people laugh, and then makes them think.” And this year’s crop of winners once again succeeds at those tasks.

Share

Read more
Posted in neurology | Tagged Atlantic Salmon, bioworld, Leibniz Institute Facilitation

‘Final Chapter’ on XMRV? Good Luck With That One

September 24, 2012 – 11:42 am | By Anette Breindl | 1 comment

blog 9-24-12

Viruses are on the border between living and dead. So are the theories about what some of them cause.

Share

Read more
Posted in chronic fatigue syndrome, prostate cancer, Vaccine, virus | Tagged CFS, Ian Lipkin, Judy Mikovits, XMRV

Life Isn’t as Sweet as it May Seem in Biotech’s C-Suites

September 18, 2012 – 5:12 pm | By Michael Harris | No comments yet

P

Biotechnology is an idiosyncratic industry in which some executives can stake their careers on the pursuit of orphan drugs that, at best, will offer only limited opportunity for corporate profits and investors returns, while addressing the usually unmet needs of…

Share

Read more
Posted in Biotechnology, executive salaries | Tagged Kevin Sharer, Roger Perlmutter, ROI, VP

Grappling with the Ethics

September 5, 2012 – 9:45 am | By Mari Serebrov | No comments yet

e

With science boldly taking us where we’ve never gone before, we’re exploring new worlds and stretching the boundaries of our universe. While these are exciting times for the adventurer in us, they can be discomfiting for our inner ethicist.

Share

Read more
Posted in bioethics, embryonic stem cell research, ethics, genetics, Vaccine | Tagged Fay Boozman, Federal Circuit, Judge Pauline Newman, Vaccine Act

Where’s Rube Goldberg When You Need Him?

August 8, 2012 – 10:36 am | By Mari Serebrov | 2 comments

goldberg 8-8-12

What’s the difference between Congress and a Rube Goldberg contraption?

Share

Read more
Posted in antibiotics, Biotechnology, Congress, FDA, Financing | Tagged FDASIA, Hatch Waxman, Optimer Pharmaceuticals Inc, Rube Goldberg

Is it Better to Forgive and Pharm-merge?

August 6, 2012 – 4:26 pm | By Michael Harris | No comments yet

F

Aug. 5 was International Forgiveness Day, and the founding organization of this annual effort, Worldwide Forgiveness Alliance (WFA), says in its mission statement that a goal is to promote and publicize the research findings that show forgiveness creates better health,…

Share

Read more
Posted in aging, Big pharma, Biotechnology, M&A | Tagged Forgiveness Day, International Forgiveness Day, WFA
« Previous 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15 Next »

About this Blog

BioWorld Perspectives is the official blog for news, analysis, debates, commentary and camaraderie related to the development of biotechnology drugs.

Join the Conversation

 Facebook Twitter LinkedIn YouTube RSS

Subscribe to our Blog

Recent Posts

  • Biotech’s White Knight (aka Serial Cheater) Gets Prison Time, Finally
  • Where’s Superman When He’s Needed?
  • Biopeople to Meet at BIO2013: Inside the World of Biotech’s Luminaries, Titans and Brainiacs
  • Cancer Research Through Time: Cure Should’ve Been Wrapped up by 1985
  • ‘ImaginAb’ That! BioWorld Salutes ‘Overall Awesomeness’

Categories

  • Accelerated approval (2)
  • acquisition (1)
  • acute kidney injury (1)
  • aging (1)
  • AIDS (1)
  • antibiotics (2)
  • Antibody (2)
  • Autism (1)
  • Big pharma (28)
  • bioethics (4)
  • Biologic (8)
  • Biosimilar (10)
  • Biotech conferences (9)
  • Biotechnology (95)
  • Biotechnology Industry Organization (8)
  • BLA (3)
  • Cancer (16)
  • Cardiovascular (2)
  • China (4)
  • chronic fatigue syndrome (3)
  • Clinic (4)
  • Clinical Trial (14)
  • Collaboration (5)
  • Complete Response Letter (4)
  • Congress (2)
  • Deals (6)
  • Diabetes (1)
  • DNA (2)
  • Drug Approval (13)
  • drug importation (1)
  • embryonic stem cell research (1)
  • emerging markets (2)
  • epilepsy (1)
  • ethics (1)
  • European Medicines Agency (5)
  • evolution (1)
  • executive salaries (1)
  • FDA (23)
  • Financing (24)
  • FOB (1)
  • Follow-on biologic (2)
  • FTC (1)
  • Gene Therapy (5)
  • generic (2)
  • genetics (4)
  • Genomics (7)
  • Healthcare reform (4)
  • HIV (1)
  • immunotherapy (4)
  • IND (2)
  • Investigational New Drug Application (3)
  • IPO (4)
  • License (2)
  • M&A (6)
  • multidrug resistance (1)
  • mutation (1)
  • National Institutes of Health (1)
  • NDA (3)
  • neurology (3)
  • neuroprostheses (1)
  • neuroprosthetic (1)
  • New Drug Application (7)
  • Obesity (1)
  • OIG (1)
  • Orphan disease (7)
  • pandemic (1)
  • partnering (1)
  • patent cliff (2)
  • Patents (4)
  • PDUFA (4)
  • Personalized medicine (4)
  • Pharmaceutical (21)
  • Phase I (5)
  • Phase II (4)
  • Phase III (6)
  • Pipeline (6)
  • Preclinical (2)
  • prostate cancer (1)
  • Rare disease (3)
  • Reimbursement (9)
  • REMS (1)
  • RNAi (2)
  • SEC (1)
  • sequestration (1)
  • Series A (1)
  • Shareholder value (1)
  • siRNA (2)
  • Stem cell (2)
  • Supplemental new drug application (2)
  • TB (1)
  • traumatic brain injury (1)
  • Tuberculosis (2)
  • Type 2 Diabetes (1)
  • Uncategorized (14)
  • Vaccine (4)
  • venture captial (7)
  • Video (5)
  • virus (2)

Tags

ABH ASCO BIO Biotechnology Industry Organization bioworld BRIC Celgene Corp CEO CFS China Clovis Oncology Inc Cynthia Robbins Roth Day Four Day Three Day Two Dendreon Corp DNA EST EU FDA HCV Hemispherx Biopharma Inc HIV IPO Janssen Labs Mari Serebrov MBA Morgan Healthcare Conference New York New York Times NIH Nobel Prize PDUFA Pfizer Inc PR RNA Roche ROI San Diego San Francisco Seattle Genetics Inc SEC UK VC Vivus Inc

Recommended Blogs

  • Inside Bio
  • Patently Biotech
  • The Catalyst

Recommended Organizations

  • American Society of Clinical Oncology
  • American Society of Hematology
  • BayBio
  • BioIndustry Association
  • Biotechnology Industry Organization

Twitter Updates

    Part of Thompson Media Group LLC: Thompson.com | Sheshunoff.com | ASPratt.com | BioWorld.com | CMEweb.com | Performanceweb.org | ASMIweb.com
    © Copyright 2013 | BioWorld